CRISPR THERAPEUTICS AG (CRSP)
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
📉 **NEGATIVE** • Low confidence analysis (53%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (45%) **Content type:** Clinical